Recombinant Human CD30 Ligand/TNFSF8 Protein(His Tag)

SKU: PDMH100341

Size:100μg

Storage:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping:This product is provided as lyophilized powder which is shipped with ice packs.

Exp date:12 months

Category ID_II:Recombinant Proteins

Category ID_III:Cytokines

Abbreviation:CD30 Ligand/TNFSF8

Target Synonym:PSOR;CD antigen CD;Tumor necrosis factor ligand superfamily member;TNFSF;S100A;TNFSF8;CD153;CD30L;CD30LG;TNLG3A;CD antigen CD153;CD30 ligand;CD30-L;sCD30 Ligand;soluble CD30 Ligand;Tumor necrosis factor ligand superfamily member 8;S100A7;PSOR1;S100A7C; TNFSF8

Research Areas:Immunology

Conjugation:

Target Species:Human

Expression Host:Mammalian

Application:

Fusion tag:C-His

UNIProt ID:P32971

Accession:P32971

Background:CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals throμgh CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been sμggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.

Concentration:

Activity:Not validated for activity

Sequence:Val63-Asp234

Purity: > 90% as determined by reducing SDS-PAGE.

Formulation:Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Endotoxin:< 1.0 EU/mg of the protein as determined by the LAL method.

Calculated MW:18.8 kDa

ObservedMW:40 kDa